Primary model receiver operating curve characteristics.

<p>Primary model receiver operating curve characteristics.</p

Characteristics of Subjects (n = 1307).

<p>Characteristics of Subjects (n = 1307).</p

Model Characteristics.

<p>Model Characteristics.</p

Consort diagram of study flow.

<p>Consort diagram of study flow.</p

Univariate analyses of candidate predictor variables for inpatient-mortality.

<p>Univariate analyses of candidate predictor variables for inpatient-mortality.</p

Disposition of randomized study participants.

<p>Disposition of randomized study participants.</p

Demographics of Study Participants.

<p>* Data missing for 2 patients</p><p>Demographics of Study Participants.</p

Per-protocol survival analysis of time from randomization (Deferred Treatment arm) or cessation of immediate ART (Immediate Treatment arm) until permanent initiation of antiretroviral therapy (ART).

<p>Results are stratified by study arm (Immediate ART vs. Deferred ART). The Immediate ART arm includes the 37 subjects who completed the study protocol, i.e., 12 months of ART followed by cessation of ART and continuation of clinical monitoring. Numbers of observations at 6-monthly time points are shown. (For the results of the same analysis including the 9 subjects in the Immediate arm who completed 12 months of ART but did not stop ART at that time, see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0143259#pone.0143259.s003" target="_blank">S1 Fig</a>).</p

The effect of CHS on the probability of persistent HCV infection, specific psychosis diagnosis, drug trafficking criminal activity, and multimorbidity score.

<p>Estimated effect curve (black line) and 95% CI (red, dashed line) are presented for each plot. Panels A and B show the effect display of the influence of CHS on the probability of of persistent HCV infection in males (A) and females (B) adjusting for age. The vertical axis displays the probability of having an active HCV infection at the first serology screen. Panel C shows the effect display of the influence of CHS on psychosis diagnoses, controlling for age and sex. The vertical axis of each display is the probability of substance-induced psychosis, functional psychosis, PNOS, or no psychosis diagnosis, respectively. Panel D shows the effect display of the influence of CHS on the probability of engaging in drug trafficking, adjusting for age and sex. The vertical axis displays the probability of a drug trafficking crime being reported at the baseline assessment. Panel E shows the effect display of the association between CHS and the cumulative probability of having one or more of twelve multimorbid illnesses. Colored bands represent multimorbidity score, ranging from 0-8 in this display. </p

Composite harm scores.

<p>Panel A shows the distribution of Composite Harm Scores of the cohort from the first month of study. Panel B shows the prevalence of types of substance use during the first month of study across CHS quartile groups. MA: methamphetamine. Panel C shows the number of subjects in CHS quartile groups using multiple substances during the first month of study. Panel D shows the mean sum of the number of days using each substance during the first four weeks of the study for CHS quartile groups. Colors represent individual drugs, ordered from top to bottom in decreasing ISCD harm to user scores. Error bars indicate SD. Panel E shows the mean CHS for each CHS quartile group, colors indicating the contribution of harm from each substance (ISCD drug harm score * frequency) to the mean CHS value for the quartile group. Error bars indicate SD. </p